EUVIMEDEUVIMED entdecken
KohortenstudieQuerschnittstudieOpen Access · CC BY 4.0

Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China

Hangjie Zhang iD, Qianhui Hua, Nani Nani Xu, Xinpei Zhang, Bo Chen, Xijun Ma, Jie Hu, Zhongbing Chen, Pengfei Yu, Huijun Lei, Shenyu Wang, Linling Ding und 5 weitere

eLife · 2023

DOI: 10.7554/elife.84056 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift eLife, 2023. Verfasst von Hangjie Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Zhejiang Province, Key Program of Health Commission of Zhejiang Province/ Science Foundation of National Health Commission, Major program of Zhejiang Municipal Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although inactivated COVID-19 vaccines are proven to be safe and effective in the general population, the dynamic response and duration of antibodies after vaccination in the real world should be further assessed.

Methods

We enrolled 1067 volunteers who had been vaccinated with one or two doses of CoronaVac in Zhejiang Province, China. Another 90 healthy adults without previous vaccinations were recruited and vaccinated with three doses of CoronaVac, 28 days and 6 months apart. Serum samples were collected from multiple timepoints and analyzed for specific IgM/IgG and neutralizing antibodies (NAbs) for immunogenicity evaluation. Antibody responses to the Delta and Omicron variants were measured by pseudovirus-based neutralization tests.

Results

Our results revealed that binding antibody IgM peaked 14–28 days after one dose of CoronaVac, while IgG and NAbs peaked approximately 1 month after the second dose then declined slightly over time. Antibody responses had waned by month 6 after vaccination and became undetectable in the majority of individuals at 12 months. Levels of NAbs to live SARS-CoV-2 were correlated with anti-SARS-CoV-2 IgG and NAbs to pseudovirus, but not IgM. Homologous booster around 6 months after primary vaccination activated anamnestic immunity and raised NAbs 25.5-fold. The neutralized fraction subsequently rose to 36.0% for Delta (p=0.03) and 4.3% for Omicron (p=0.004), and the response rate for Omicron rose from 7.9% (7/89)–17.8% (16/90).

Conclusions

Two doses of CoronaVac vaccine resulted in limited protection over a short duration. The inactivated vaccine booster can reverse the decrease of antibody levels to prime strain, but it does not elicit potent neutralization against Omicron; therefore, the optimization of booster procedures is vital. Funding: Key Research and Development Program of Zhejiang Province; Key Program of Health Commission of Zhejiang Province/ Science Foundation of National Health Commission; Major Program of Zhejiang Municipal Natural Science Foundation; Explorer Program of Zhejiang Municipal Natural Science Foundation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19AdultHumansCohort StudiesCross-Sectional StudiesSARS-CoV-2Antibodies, NeutralizingImmunoglobulin GAntibodies, ViralChinaVaccines, Inactivated

Stichwörter der Autor:innen

COVID-19epidemiologyglobal healthhumanhumoral immunityimmunologyinflammationvacicne

Substanzen

COVID-19 VaccinesAntibodies, NeutralizingImmunoglobulin GAntibodies, Viralsinovac COVID-19 vaccineVaccines, Inactivated

Autor:innen und Institutionen

  • Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • School of Medicine, Ningbo University, Ningbo, China.
  • Xihu District Center for Disease Control and Prevention, Hangzhou, China.
  • Shangyu District Center for Disease Control and Prevention, Shaoxing, China.
  • Kaihua District Center for Disease Control and Prevention, Quzhou, China.
  • Yuecheng District Center for Disease Control and Prevention, Shaoxing, China.

ORCID-Profile: Hangjie Zhang, Jianmin Jiang, Huakun Lv

Förderung

  • Key Research and Development Program of Zhejiang Province
  • Key Program of Health Commission of Zhejiang Province/ Science Foundation of National Health Commission
  • Major program of Zhejiang Municipal Natural Science Foundation
  • Explorer Program of Zhejiang Municipal Natural Science Foundation

Zitieren

APA

Zhang, H., Hua, Q., Nani Xu, N., Zhang, X., Chen, B., Ma, X., Hu, J., Chen, Z., Yu, P., Lei, H., Wang, S., Ding, L., Fu, J., Liao, Y., Yang, J., Jiang, J., & Lv, H. (2023). Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China. eLife. https://doi.org/10.7554/elife.84056

Vancouver

Zhang H, Hua Q, Nani Xu N, Zhang X, Chen B, Ma X, et al. Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China. eLife. 2023. doi:10.7554/elife.84056

BibTeX
@article{Zhang2023,
  author = {Zhang, Hangjie and Hua, Qianhui and Nani Xu, Nani and Zhang, Xinpei and Chen, Bo and Ma, Xijun and Hu, Jie and Chen, Zhongbing and Yu, Pengfei and Lei, Huijun and Wang, Shenyu and Ding, Linling and Fu, Jian and Liao, Yuting and Yang, Juan and Jiang, Jianmin and Lv, Huakun},
  title = {Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China},
  journal = {eLife},
  year = {2023},
  doi = {10.7554/elife.84056}
}
Kostenlos starten →